Chris Boshoff: Pfizer has entered into a clinical trial collaboration with Summit Therapeutics
Chris Boshoff, Chief Oncology Officer and President of Research and Development at Pfizer, shared a post on LinkedIn:
“I’m pleased to share that Pfizer has entered into a clinical trial collaboration with Summit Therapeutics, Inc. that has the potential to meaningfully advance targeted therapies for multiple difficult-to-treat cancers.
Our collaboration will explore the opportunity to combine several of our ADCs with Summit’s novel, investigational PD-1 / VEGF bispecific antibody, advancing research that could bring forth novel combinations across multiple solid tumors.
Cancer’s complexities require innovative approaches, and we are excited to join forces with Summit to investigate how these modalities can be brought together to attack the disease from potential complementary angles.
Read the press release here.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023